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Mini-abstract 
Understanding the cost of hip fractures is important in informing policy decisions on preventative 
treatments. We reviewed the literature for studies reporting costs of hip fractures and identified 113 
studies. We estimate the initial hospitalisation to cost $10,075 with significant variation by region, 
gender and year of study. 
Abstract  
Purpose – To systematically review the costs of hip fractures globally and identify drivers of 
differences in costs.  
Methods – A systematic review was conducted to identify studies reporting patient level fragility hip 
fracture costs between 1990 and 2015. We extracted data on the participants and costs from these 
studies. Cost data concerning the index hospitalisation were pooled and a meta-regression was used 
to examine its potential drivers. We also pooled data on the first year costs following hip fracture 
and considered healthcare, social care as well as other cost categories if reported by studies.  
Results – 113 studies reported costs of hip fracture based on patient level data. Patients developing 
complications as well as patients enrolled in intervention arms of comparative studies were found to 
have significantly higher costs compared to the controls. The pooled estimate of the cost for the 
index hospitalisation was $10,075. Health and social care costs at 12 months were $43,669 with 
inpatient costs being their major driver. Meta-regression analysis identified age, gender and 
geographic region as being significantly associated with the differences in costs for the index 
hospitalisation.  
Conclusions – Hip fracture poses a significant economic burden and variation exists in their costs 
across different regions. We found that there was a considerable variation across studies in terms of 
study design, methodology, follow up period, costs considered and results reported that highlights 
the need for more standardisation in this area of research.   
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Introduction 
Hip fractures are an important cause of death and disability worldwide, particularly amongst older 
people. They are associated with physical and mental disability as well as high mortality and hospital 
costs [1-3]. In 1990 it was estimated that, globally, there were 1.6 million hip fractures [4]. Due to an 
ageing population, the number of hip fractures is expected to rise steeply, especially in Asia [5,4]. By 
2050, the annual incidence of hip fracture worldwide will rise to over 6 million [6]. 
A history of falls and underlying osteoporosis are the leading risk factors for sustaining a fragility hip 
fracture in older age [7,8]. Bone mineral density decreases with age and at a faster rate in women 
[9]. Consequently, the prevalence of osteoporosis and hip fractures are highest in older women [10]. 
In 2000, it was estimated that 23% of post-menopausal white women in the United States of 
America (US) were living with osteoporosis and a further 54% had osteopenia, a milder form of the 
disease [4]. Together, osteoporosis and osteopenia account for over five million Disability Adjusted 
Life Years (DALYs) annually [11]. Fragility hip fractures contribute more than 40% of the DALYs 
caused by osteoporosis [2]. The mortality rates of these individuals vary between 8.1-10.5% at 30 
days and 21.6-31.2% at one year [12,3,13].  
Evidence accumulates on interventions to reduce the burden of disease from hip fractures by 
preventing falls; optimising hospital recovery; implementing secondary fracture prevention services, 
e.g. fracture liaison services; and diagnosing and treating osteoporosis with bone resorptive drugs. 
Policy decisions regarding investing in new services or interventions require up-to-date knowledge of 
the economic burden of hip fracture and cost-effectiveness analyses of the interventions being 
considered. Accurate data on the cost of hip fractures is an essential consideration when estimating 
the impact of hip fractures and osteoporosis as well as being a major input in cost-effectiveness 
analyses.  
The aim of this study is to systematically review the costs of fragility hip fractures globally and, 
where possible, identify the key drivers of the differences in costs.  
Methods 
Literature search 
The selection of electronic databases and the search strategy were developed with an information 
specialist at the University of Oxford and in line with preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) [14]. MEDLINE, Embase, EconLit, Global Health, CAB abstracts, 
NHS EED & HTA and Web of science databases were searched (see Appendix 1 for search strategies).  
Study selection 
The outcome of interest was the cost of hip fracture. Studies reporting costs based on patient level 
datasets were included. Studies published before 1990, or if the year of costing was before 1990 
were excluded. Studies not in English and not published in peer-reviewed journals were also 
excluded. Where multiple studies used the same patient cohort, data extraction was restricted to 
the paper reporting the most detailed information.  
References were searched to identify studies missed by the electronic search. The grey literature 
was not reviewed.  
 
Data extraction and management 
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Data were extracted from included studies using a standardised data sheet by two reviewers (see 
Appendix 2). Comparison of data extracted by reviewers was performed for 88 studies (78%). 
Discrepancies between reviewers were resolved through discussion among authors.  
Data extracted included details on study design, sample population, economic perspective and 
results of the study. Follow up was assumed to be the mean length of stay for studies reporting only 
costs for the initial hospital inpatient admission. Additional factors related to the country in which 
participants lived were obtained from World Bank datasets. Data were extracted on Gross Domestic 
Product (GDP), national healthcare expenditure per capita and the proportion of total healthcare 
expenditure that was public [15-17].  
Risk of bias was assessed using a 14 point quality checklist based on what was used in National 
Institute for Health and Care Excellence (NICE) guidelines for evaluating costing studies economic 
evaluations (Appendix 3) [18]. Quality scores from researchers were cross checked for 86 studies 
(76%).  
Results of subgroup or regression analysis were extracted with details of the variables assessed. 
Results were coded as being associated with either significantly higher or lower costs (p<0.05) or 
with no difference in costs.   
All reported costs were extracted as mean costs per patient. If studies reported the total cost 
incurred by a cohort, the mean cost per patient was imputed. Costs were assigned to the 
category(ies) of care the cost related to (see Figure A5.4 in Appendix 5). Details of the subgroup and 
follow-up period for each cost were also extracted. Where studies reported multiple costs (e.g. for 
different sub-groups, categories of care or follow-up periods), each cost was extracted separately. 
Where different studies reported costs for the same population but at different follow-up time 
points we extracted costs for the non-overlapping periods. Where reported, standard error was 
extracted or imputed using standard deviation and sample size or from confidence intervals.  
All costs are presented in 2014 US international dollars. Costs were converted to 2014 prices [19], 
and then to US dollars adjusted for cost of living using the purchasing power parity (PPP) method 
[20].  
Statistical analysis 
Sample size and quality scores were pooled as unweighted means. Pooled estimates for gender, age, 
length of stay and operation performed were weighted using the sample size. Secular trend in study 
quality was assessed using an ordinary least squares model.  
Pooled estimates of costs were calculated using the inverse variance (1/SE2) method [21]. Given the 
expected variation in follow-up time of data collection, we focused on costs occurring in two time 
periods: index hospitalisation and at 12 months following hip fracture. Hence, we only pooled 
studies reporting costs at these time points. The index hospitalisation refers to the initial inpatient 
admission immediately following hip fracture. 
Where studies reported more than one cost, a two-level approach was used to pool costs allowing 
for grouping of costs within studies. At the cost level, the standard error for costs informed the 
weights. At the study level, weighting was calculated by estimating the pooled standard deviation 
before converting to a standard error. It was assumed that costs for subgroups were independent of 
each other. The use of a two level approach was contingent on the number of costs available. If too 
few costs were available (i.e. n<10), or the costs were from a single study, pooled estimates were 
calculated without using the multi-level approach.  
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A two-level meta-regression was used to explore the association between initial hospitalisation costs 
and potential predictors of costs. The approach combines the pooling of cost data from different 
studies using a meta-analysis, accounting for within and between-study variation, using a 
generalised linear model with Gaussian family and identity link to estimate the costs given the 
sample characteristics. Covariates were judged to be statistically significant if p<0.05. We focused on 
index hospitalisation costs due to the expectation that they were the most commonly reported and 
consistent costs across all studies and represented a major contributor to costs during the first year 
following a hip fracture [3].  
Where studies reported the total healthcare cost as well as costs for individual categories of care 
(e.g. inpatient care) at 12 months, the proportions of individual categories of care expressed in 
terms of total healthcare costs were estimated. The average of these proportions was used to 
estimate the proportion of total healthcare costs attributable to each category of care. Similarly, in 
studies reporting social care costs additionally to healthcare costs, the proportion of the social care 
costs as a percentage of total health and social care costs was estimated. All statistical analysis was 
performed using Stata 12 (Stata Corp, USA). 
Results 
Descriptive analysis 
The literature search identified 113 studies that met the inclusion criteria and are included in the 
analysis (see Figure 1). Appendix 4 provides further information of included studies.  
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Figure 1 – PRISMA® Flow Diagram 
 
The 113 papers presented costs of hip fractures for 670,173 patients. The mean sample size was 
5,930 (median 252, range 4 to 126,374). Table 1 presents details of the studies and details of 
enrolled patients. The average age at hip fracture was 80.2 years and the majority of patients were 
females (70.1%). During index hospitalisation, the most common surgical procedures were internal 
fixation and hemi-arthroplasty (89%). The mean length of stay for the index hospitalisation was 8.6 
days (SE 1.1). However, mean length of stay varied significantly by region. Studies from North 
America reported the shortest mean length of stay, whilst studies from Asia had the longest length 
of stay. 
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Table 1 – Baseline characteristics of enrolled participants. 
 Mean (SE) 
Number of studies 
reporting data 
Study details 
Sample size a 5,931 (1,575) 113 
Study quality a 71.1% (1.6) 113 
Demographic details 
Age (years) b 80.2 (0.87) 102 
Gender (% female) b 70.1% (5.7) 104 
Length of stay, index 
hospitalisation (days) b 
North America 6.4 (0.21) 21 
Western Europe 13.6 (1.08) 25 
Asia 32.1 (5.7) 8 
Australasia 19.8 (2.8) 3 
Latin America 10.9 (1.7) 2 
Eastern Europe No data 0 
Middle East 9.6 (1.5) 3 
Total 8.6 (1.1) 62 
Operation performed b 
Internal fixation 46.6% (5.8) 
31 
Hemi-arthroplasty 41.2% (4.7) 
Total hip 
replacement 3.0% (1.2) 
Intramedullary nail 1.2% (0.7) 
Other 8.0% (0.05) 
a – unweighted  
b – weighted by sample size 
Year of publication and study quality 
The year of publication of included studies ranged from 1993 to 2015. The majority of studies (n=63, 
56%) were published after 2007. Average study quality was 71%. We found no significant association 
between study quality and year of publication (p=0.359).  
Geography 
Costs were available from 27 different countries (see Table A5.3 in Appendix 5). The majority of 
studies assessed costs of hip fractures in North America or Western Europe (n=50, 44% and n=40, 
35% respectively). There were 11 studies from Asia, with Australasia, Latin America, Eastern Europe 
and the Middle East accounted for the remaining twelve studies. No studies were identified for the 
African region.  
Study design  
The majority of studies (n=103, 91%) used an observational design with the remaining 10 studies 
(9%) assessing costs as part of a randomised controlled study. Of observational studies, 71 (69%) 
assessed the cost of hip fractures retrospectively, 28 (27%) studies used a prospective design and 
four studies used a cross sectional design (4%). 
Economic perspective and costing methodology 
The economic perspective of the included studies was explicitly stated in 33 papers and was derived 
from information provided within the study for the remaining studies. A payer perspective (e.g. 
HMO, Private insurer) was the most common (n=36, 32%), followed by a healthcare provider (e.g. 
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hospital, primary care) perspective (n=35, 31%). A healthcare system perspective (e.g. National 
Health System) was adopted in 26 studies (23%) and a societal perspective taken in the remaining 16 
studies (14%).  Studies from North America were more likely to adopt a payer perspective and 
studies from Western Europe were more likely to take a system perspective (χ2, p<0.001).  
Resource use in the majority of studies was valued using national reference costs (n=51, 45%) or 
costs from local finance departments (n=50, 44%). Ten studies (9%) used a combination of costs 
from national reference databases and local finance departments. The costing methodology was not 
stated or was unclear in two studies (2%).  
Follow up period 
Nearly half of included studies (48 studies, 42%) only reported costs related to the index 
hospitalisation. The most commonly reported length of follow up after the index hospitalisation was 
12 months (38 studies, 34%). Fourteen studies (12%) reported a follow up period between the index 
hospitalisation and 12 months. The remaining 13 studies reported a follow-up period of more than 
12 months. The majority of these (eight studies) reported a follow-up of 24 months (see Table A5.5 
and A5.6 in Appendix 5). 
Subgroup analysis  
Subgroup analysis was performed by 44 studies (39%). Eleven of these used multivariate analysis to 
explain the variation in costs by adjusting for several variables. Subgroup analysis was conducted on 
costs covering a range of different categories of care. Twenty-two studies conducted sub-group or 
regression analysis on index hospitalisation costs, seven on healthcare costs, 10 on direct costs and 
five on total costs. Of studies conducting sub-group analysis on healthcare, direct or total costs, six 
also reported sub-group analysis for the index hospitalisation resulting in a total of 28 studies 
reporting results of sub-group analysis for this category of care. Table 2 shows the number of studies 
assessing each variable and the direction of the association with costs.  
Comorbidities prior to fracture were found to be associated with significantly higher costs in 80% of 
studies assessing this variable. Developing a complication after hip fracture was found to be 
associated with significantly higher costs in 93% of studies assessing this variable.  
Female gender, internal fixation and enrolment in the intervention arm of a study (relative to control 
arm) were commonly associated with a significant decrease in costs relative to the reference group. 
Females were reported to be associated with statistically significant lower costs than males in six of 
the 14 studies in which gender was analysed. However, one study reported females to be associated 
with significantly higher costs than males. 
There was limited or contradictory evidence of the association between costs and mean age of the 
sample, ethnicity, insurance status, residence prior to admission, functional status prior to 
admission, type of hip fracture and discharge destination.  
Results of sub-group analysis for index hospitalisation costs reveal similar findings.  
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Table 2 - Number of studies reporting results of sub-group or regression analysis. Breakdown of 
the number of studies finding statistically significant difference in results between groups (at the 
95% confidence level).  
Reported results of sub-group analysis by variable assessed (all costs, n=44) 
Subgroup Number of studies  
Results of subgroup or regression analysis 
Lower costs No difference Higher costs 
Older age 12 (11%) 2 6 4 
Female gender 14 (12%) 6 7 1 
Black and minority ethnicity 
(vs. white) 2 (2%) 0 1 1 
Not resident in own home 
prior to admission 3 (3%) 1 1 1 
Private insurance 1 (1%) 0 0 1 
Impaired functional ability 
prior to fracture 2 (2%) 1 1 0 
Comorbidity prior 15 (13%) 0 3 12 
Inter-trochanteric fracture 
vs. neck of femur 4 (4%) 0 3 1 
Internal fixation vs. 
hemiarthroplasty a 10 (9%) 4 6 0 
Intervention protocol 7 (6%) 4 3 0 
Developed complication  14 (12%) 0 1 13 
Not discharged to own 
home 5 (4%) 0 2 3 
Reported results of sub-group analysis by variable assessed (index hospitalisation costs, n=28) 
Subgroup Number of studies  
Results of subgroup or regression analysis 
Lower costs No difference Higher costs 
Older age 6 (5%) 1 4 1 
Female gender 9 (8%) 4 5 0 
Black and minority ethnicity 
(vs. white) 2 (2%) 0 1 1 
Not resident in own home 
prior to admission 1 (1%) 0 1 0 
Impaired functional ability 
prior to fracture 1 (1%) 0 1 0 
Comorbidity prior 10 (9%) 0 1 9 
Inter-trochanteric fracture 
vs. neck of femur 3 (3%) 0 2 1 
Internal fixation vs. 
hemiarthroplasty a 7 (6%) 3 4 0 
Intervention protocol 5 (4%) 5 0 0 
Developed complication  10 (9%) 0 0 10 
Not discharged to own 
home 3 (3%) 0 2 1 
a –Except Gill et al which compared internal fixation to intramedullary nail.   
 
  
9 
 
Hip fracture costs  
In total, 607 costs were extracted from included studies, relating to all categories of care and a range 
of different follow-up periods. A standard error was available or imputed for 243 costs. Of these, 178 
costs related to a single category of care (e.g. inpatient care) and 65 related to multiple categories of 
care (e.g. a combination of inpatient, outpatient and community care).  
Index hospitalisation costs 
Costs for the index hospitalisation were reported in 68 studies, providing 126 separate costs. This 
comprised 48 studies solely reporting index hospitalisation costs and 20 studies reporting costs for a 
longer follow-up but reporting separately the costs of index hospitalisation. Of these, 64 costs from 
32 studies were reported with a standard error (Table A5.5, Appendix 5). The pooled mean cost for 
the index hospitalisation was $10,075 (95% CI $8,322-$11,828).  
Univariate analysis of index hospitalisation costs 
Results of univariate multi-level regression analysis are available in Table A5.8 (Appendix 5). Certain 
geographic regions, studies reporting charges as opposed to costs, control groups of comparative 
studies, randomised controlled trials, post-fracture complications, older age, males, longer mean 
length of stay and older studies were associated with significantly higher costs.  
Multivariate analysis of index hospitalisation costs 
Results of the multivariate analysis are reported in Table A5.8 (Appendix 5). To avoid overfitting, 
studies from the US were compared with others. We found gender, year of study, US studies, and 
length of stay to be significantly associated with costs. Holding all else constant, studies published 
more recently were significantly associated with lower costs which may represent changes in clinical 
practice, fewer complications as well as methodological changes. 
Furthermore, holding all else constant, in studies outside the US the mean cost per patient was 
$3,304 less per additional day of length of stay compared to the US. On average, women were found 
to be statistically significantly less expensive than men, costing $134 less per patient (p<0.001).  
The main source of variation between cost estimates was due to variation between studies as 
opposed to within studies (ICC=0.939).  
Costs after index hospitalisation 
Of the 607 costs extracted, 481 costs related to categories of care from a variety of follow-up 
periods not specific to the index hospitalisation (e.g. index rehabilitation, community healthcare 
costs, social care costs, productivity losses or aggregated costs combining several categories into a 
single figure). Of these, 179 costs were reported with standard errors, of which nine comprised index 
rehabilitation costs and the remaining 170 costs covered a range of follow-up periods from 45 days 
to 36 months (see Table A5.5 and A5.6 in Appendix 5).  
 
The pooled estimate for index rehabilitation costs was $7,496 (SE 4,688) based on four costs. The 
pooled estimate for the combined cost of the index hospitalisation and rehabilitation combined was 
$11,767 (SE 571), based on five costs reporting a summary cost.  
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Hip fracture costs at 12 months 
After the index hospitalisation, the most commonly reported follow up period was 12 months (228 
costs). Of these, 81 costs were reported with a standard error. Pooled costs for each category of care 
at 12 months following hip fracture are reported in Table 3. 
Table 3 - Pooled mean costs for different categories of care at 12 months. 
Category of care Number of 
Costs 
Average cost (SE)a 
Inpatient a 13 13,331 (2,843) 
Inpatient (excluding index hospitalisation) b 3 1,311 (1,178) 
Rehabilitation (index and subsequent 
rehabilitation) b 
3 12,020 (3,330) 
Outpatient a 7 835 (85) 
Primary care and community services b 4 543 (223) 
Medical drugs a 7 140 (31) 
Total healthcare costs a 11 13,820 (4,005) 
Medical equipment and home modification b 2 1,859 (2,387) 
Social care in the patient’s home b 4 3,742 (2,166) 
Social care in an Institutional setting b 3 2,839 (2,303) 
Total social care costs b 2 6,851 (6,960) 
Other direct cost b 2 - 
Health and social care costs a 11 43,669 (12,241) 
Out of pocket expenses 0 - 
Income foregone by caregiver b 1 426 (120) 
Income foregone by patient b 2 117 (10) 
Productivity and informal care  0 - 
Total costs a 6 11,497 (1,588) 
a - two-level approach 
b - single level approach  
The estimate for total health and social care costs in the first year following hip fracture is $43,669 
per patient. Inpatient care is the single category of care with the highest cost, estimated at $13,331. 
This is followed by the cost of rehabilitation care, estimated at $12,020. However, the figure for 
rehabilitation costs is unexpectedly high due to the limited number of costs and a very high cost 
from one study. Excluding this study resulted in a mean cost of $6,269 (2,094).  
The index hospitalisation accounts for the majority of inpatient costs during the first 12 months. 
Eight studies reported both the costs of the index hospitalisation and total inpatient costs at 12 
months (12 costs). On average, the index hospitalisation accounted for 79.6% of the total inpatient 
costs in the first year. 
Seven studies reported total healthcare costs and total inpatient costs over the first year following 
hip fracture (nine costs). Inpatient costs represented 74.3% of the total healthcare costs in the first 
year following hip fracture. Six studies (seven costs) reported total health and social care costs and 
the costs of inpatient care in the first 12 months following hip fracture. Inpatient costs represented 
62% of the total health and social care costs in the first 12 months.  
Medication costs as well as total healthcare costs at 12 months were reported by four studies (six 
costs). Medication costs comprised, on average, 7.9% of total health care costs during the first year 
following hip fracture. Only two studies (four costs) reported both the costs of primary health care 
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and total healthcare costs at 12 months. The cost of primary health care represented 7.7% of total 
healthcare costs.  
Four studies (seven costs) reported the cost of social care as well as the total health and social care 
costs at 12 months. Social care accounted for on average 24.8% of health and social care costs 
during the first 12 months following hip fracture.  
Discussion 
Our study presents results of a systematic review of the costs of fragility hip fractures globally since 
1990. We identified costs from 113 studies, including data on over 670,000 patients. Enrolled 
patients were predominantly older females from North America and Western Europe. We found the 
health and social care costs in the 12 months following hip fracture to be $43,669. The index 
hospitalisation and total inpatient costs represent significant components of total cost in the first 
year following hip fracture. This is consistent with findings of other studies [22-24].  
Variables identified as consistently associated with variation in hip fracture costs included patients 
with comorbidities prior to fracture and patients developing complications following hip fracture. 
There was some evidence that gender, fracture type and the operation performed may also be 
significantly associated with hip fracture costs. Evidence for the role of other factors such as age 
were less compelling with limited studies assessing the association or reporting conflicting results. 
There was little consistency in the variables included in subgroup and regression analysis across 
studies.  
The average cost for the index hospitalisation following hip fracture was $10,075 with significant 
heterogeneity between studies. Meta-regression analysis identified factors related to the country 
and healthcare system (e.g. region); the design of studies (e.g. interventional vs. control groups); and 
the patient sample (e.g. proportion that was female) to be statistically significant. We also found 
that, length of stay, gender, whether the study was conducted in the US and year of study were 
associated with the cost of care.  
Analysis of index hospitalisation costs identified US studies as having a different profile compared 
with studies from other countries. The cost for additional bed days during the index hospitalisation 
in US studies was $3,304 higher than non-US studies. This is due to studies in the US reporting 
shorter mean lengths of stay compared to other studies. Whilst mean costs of the index 
hospitalisation for US studies did not significantly differ from other studies (p=0.157), due to 
differences in the length of stay, studies from the US had significantly higher costs per bed day.  
Strengths and limitations 
The systematic review identified a large number of studies from a range of countries. To our 
knowledge, this is the first study to undertake a systematic review of hip fracture costs, pooling costs 
for different categories of care and conducting a meta-regression analysis to investigate potential 
reasons for the heterogeneity observed.  
The results reported in the present study can guide decisions on prevention measures and treatment 
strategies by providing insight into which patients incur the highest costs following hip fracture. 
Used in conjunction with data on benefit or utility from treatment and preventing falls, high risk 
groups can be identified that could benefit from targeted care.  
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Limitations in the number of costs meant that only costs for the index hospitalisation could be 
robustly analysed using meta-regression techniques. Nearly half of studies only reported costs for 
the index hospitalisation, thus limiting the data available for analysis of longer follow up periods.  
Whilst there were a large number of costs extracted, only 40% (243 costs) were reported with 
standard error. Consequently, with multiple different categories of care being assessed and different 
follow up periods, there were relatively few costs available to pool. Additional data would ensure 
more accurate pooled estimates of costs for different categories of care, with adjustments for 
differences between studies. 
Additional data reporting index hospitalisation costs would also allow adjusting for a wider range of 
variables. For example, studies consistently reported patients with comorbidities or developing 
complications as incurring higher costs. However, it was not possible to include these two factors in 
our meta-regression as too few costs were available for analysis.  
Many studies reported a summary cost (e.g. health and social care costs) without a breakdown of 
costs with standard deviations. Consequently, pooled estimates of 12 month costs for different 
categories of care are based on data from different studies. Hence, it was not possible to combine 
the various categories of care to obtain the total costs of hip fracture.  
Results were weighted in the analysis using the inverse variance method in line with Cochrane 
Collaboration guidelines [25]. Using this method resulted in a number of studies carrying a relatively 
large weighting. Furthermore, as variance is related to the cost figure, studies with higher costs are 
expected to have larger variance and as such will be given a lower weighting. Alternative methods 
for weighting studies included using the size of the sample or the score for methodological quality. 
None of the weighting methods were ideal and the inverse variance method was used as this is 
standard practice in meta-regression.  
Implications for Future Research 
Meta-regression is a useful tool to adjust for differences between studies. We applied this technique 
to analyse costs of hip fractures. Whilst limitations exist in the use of meta-regression analysis for 
data on costs of care, the present study shows its potential usefulness.  
Heterogeneity between studies is unavoidable. Guidelines and checklists for economic evaluations 
[26,27,18,28,29] help ensure an appropriate standard of research and reporting of results of costing 
studies. However, we identified considerable variation in study designs, perspective and costing 
methodologies adopted, follow up periods and reporting of results that impaired comparisons and 
highlight the need for more standardisation.   
The majority of studies identified in this review were observational and retrospective. In contrast, 
the most precise costs are to be obtained from prospective studies supported by a very detailed 
identification and valuation of resources. However, the optimal costing study faces a trade-off 
between the precision of the costs and the feasibility, time and costs associated with data collection. 
Furthermore, the optimal study design is a function of the research question being addressed. For 
example, costing studies alongside randomised trials could focus on estimating the expected key 
drivers of the cost differences between interventions with considerable detail and effort to the 
detriment of other costs. Comparative and cost-of-illness studies could equally be supported, in a 
relatively inexpensive way, by valid and precise costs from retrospective studies involving large 
medical databases that are comprehensive, up-to-date and of good quality.  
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Study designs should be precise and cost-effective when estimating hip fracture costs. Therefore, it 
is important that such costing studies describe and justify the study design and provide sufficient 
details on how costs were derived including items such as: demographics of the sample; the types of 
costs included; a breakdown of cost by category of care; and a measure of variation or uncertainty 
around the reported estimates. As well as facilitating future evidence synthesis exercises, this 
information would improve the methodological quality of studies 
Implications for Policy 
Policy decisions regarding which interventions to invest or disinvest in require accurate data to 
inform cost-effectiveness analyses. We have shown that the available hip fracture costs can vary 
greatly depending on the methodology, care categories included and population sampled. For 
example, the costs for medical care in the 12 months following hip fracture in the US ranged from 
$21,259-$44,200 which can significantly influence the cost-effectiveness results supporting policy 
decisions. 
This study identifies the need for policies to consider the context within which decisions are being 
made. Factors that may influence costs include the country from which costs are derived; how 
recent the costs estimates are; demographics of the sample; and the perspective of the study, 
including which costs were considered.  
Additionally, whilst inpatient care represents a large component of overall cost, other health and 
social care represent a significant financial burden. Lost productivity from patients and carers may 
also present further financial burden, however, too few studies reported these costs to draw 
conclusions. Better policy decisions can be made if all medical costs as well as social care costs and 
productivity loss are considered. This ‘societal’ perspective is also considered best practice in 
economic research [30].  
The results show that hip fractures place a high economic burden on health and social care systems. 
The costs incurred during the first year following hip fracture are greater than equivalent estimates 
for acute coronary syndrome ($32,345) and ischaemic stroke ($34,772) [31,32]. A meta-regression 
was used to combine heterogeneous studies presenting the cost of hip fracture to determine the 
factors driving costs of treatment. The impact of demographic factors such as gender, the 
methodology used to calculate costs as well as the country in which studies were conducted have 
been quantified. The results can be used to direct future research as well as identify sub-groups 
within the population that would be benefit from receiving preventative services.  
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